NCT03874897 - Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors. | Biotech Hunter

Enrollment

134

Participants

Timeline

Start Date

March 26, 2019

Primary Completion Date

March 20, 2021

Study Completion Date

January 26, 2024

Conditions

Advanced Solid Tumor

Interventions

DRUG

CAR-CLDN18.2 T-Cells

"Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses~• Chimeric Antigen Receptor T Cells Targeting Claudin18.2"

DRUG

PD-1 Monoclonal Antibody

Chimeric Antigen Receptor T Cells Targeting Claudin18.2 with PD-1

DRUG

Chemotherapy

First-line systemic therapy according to physician's choice

Trial Locations (3)

100142

Department of GI Oncology, Peking University Cancer Hospital, Beijing

310006

The First Affiliated Hospital , Zhejiang University School of Medicine, Hangzhou

450052

The First Affiliated Hospital of Zhengzhou University, Zhengzhou